BridgeMD
Oxytocin for drug relapse prevention
EU CTIS ID: 2023-504518-31-01
What this study is testing
Investigate the efficacy of Syntocinon in reducing craving for the drug (e.g. heroin, cocaine) in drug dependent individuals and in preventing relapse to drug use
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1) Primary diagnosis of substance use disorder according to DSMV criteria 2) Males and non-lactating, non-pregnant females, aged 18-55 years. 3) Patients must be willing and able to give informed consent 4) Patients must have understanding of Italian 5) Patients must provide an identity document
You likely can't join if
- 1) Major psychiatric disorders, such as Schizophrenia, Severe psychosis, Bipolar Affective Disorder, severe Depression with suicidal ideation and intention, Antisocial Personality Disorder and currently symptomatic Anxiety Disorders 2) Pregnant females and those planning a pregnancy; lactating mothers 3) Clinically significant medical condition such as cardiovascular disease (heart disease, heart attacks, abnormally high blood pressure), kidney disease, thyroid disease, epilepsy and brain trauma, that might interfere with the evaluation of the study medication or present a safety concern 4) Nasal cavity pathology (e.g. atrophic rhinitis, previous hypophysectomy, recurrent bleeding, perforation of the nasal septum) 5) Current alcohol use disorder if under pharmacological treatment 7) Any other condition that in the judgement of the investigator would preclude participation
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.